The global market for structural biology & molecular modeling techniques is anticipated to reach USD 13.1 billion by 2025 growing at an 18.2% CAGR from 2014 to 2025 (forecast period). The industry is driven by high incidence of chronic ailments with acquired drug resistance that in turn triggers the need for advanced & innovative therapeutics. Technological innovations have resulted in the development of mathematical models that facilitate the prediction of cellular functions & determination of precise structures. This helps in identifying novel leads with higher chances.
For example, potency determination of novel drug molecules via the in silico screening of 3D chemical structures accelerates the lead discovery & optimization process. Thus, it ensures greater focus on targets with high therapeutic potentials. Moreover, developments in in silico drug designing tools and the execution of a multi-disciplinary approach including molecular biology, biophysics, and computational biology may result in newer procedures. These procedures may help structural biologists understand different protein sequences and predict the exact structures of proteins.
The global structural biology & molecular modeling techniques market is categorized as per tools, applications, and regions. Based on tools, the market is segregated into visualization & analysis, SaaS & standalone modeling, databases, and others. The SaaS & standalone modeling segment held maximum shares in 2015 on account of extensive usage of computer-assisted modeling techniques & structuring in R&D. Furthermore, highly developed molecular modeling software assistance has resulted in advanced research. Hence, extensive applications in various medical disciplines can create lucrative opportunities in this segment.
In-depth research report on global structural biology & molecular modeling techniques market - http://www.grandviewresearch.com/industry-analysis/structural-biology-and-molecular-modeling-technique-market
On the basis of applications, the industry is categorized into drug discovery, drug development, and others. The drug discovery segment is expected to grow at a healthy CAGR from 2014 to 2025. It is driven by the associated advantages of molecular modeling in drug discovery. These advantages help structural biologists & researchers recognize critical gaps that limit the process of drug discovery, thereby yielding a comparatively reduced drug attrition rate.
As per geographies, the global market is divided into the Middle East & Africa (MEA), Asia-Pacific (APAC), North America, Latin America, and Europe. North America dominated the worldwide industry in 2015. Presence of a large pool of well-established pharma companies is a key regional driver. Moreover, these companies are actively involved in the commercialization of in silico tools in order to promote their use. APAC is expected to grow at a favorable CAGR over the forecast period. This is mainly due to supportive government initiative programs that encourage R&D activities and the emerging trend of outsourcing drug development by developed countries.
Dassault Systèmes and Chemical Computing Group are two key companies operating in the global market. Computational developments in software, agreements for drug development, and mergers & acquisitions are key strategies adopted by major industry players for larger shares. Recently, the Chemical Computing Group launched the novel version of PSILO 2016.10, its protein structure database. This updated database system includes a number of new attributes as well as enhancements for viewing the records and for searching & aligning proteins.